ARTES offers a range of vaccine producing cell lines and processes for out-licensing and technology transfer. All listed cell lines are based on our safe and high yield expression system Hansenula polymorpha.

Hepati­tis Blicensed world­wide; new tech­nol­ogy with improved yield; cell line and pcro­cess avail­able
Avian Flupre-clinical PoC; based on METAVAX® VLP plat­form highly immuno­genic, adjuvant-free; cell line and process avail­able
(L1-6; –11; –16; –18; –58)
cell lines for the dif­fer­ent serotypes avail­able; process to be devel­oped; devel­op­ment time for the process approx. 18 months

To obtain a quote, please contact us at info(at) indicating name of the vaccine of interest to you. We will revert to you with a dedicated offer specifying delivery times and costs.